Arthur Franken has been with Gilde since 2001. His investments at Gilde include Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by CR Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ) and STAT-Dx (acquired by QIAGEN). He has also been closely involved in additional investments and divestments, including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Axonics (IPO on NASDAQ), Calypso Biotech, Eargo (IPO on NASDAQ), uniQure (IPO on NASDAQ). ), BG Medicine (IPO on NASDAQ), CVRx, FIRE1 and Pieris (IPO on NASDAQ).

He represents Gilde as a member of the Supervisory Board of Calypso, Levicept, Moximed and Noema Pharma and was a member of the Supervisory Board of Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until its sale or IPO.

Before he was active at Gilde, he was active in cardiovascular research in a collaboration between the Leiden / Amsterdam Center for Drug Research and TNO Pharma. He has a masters degree in Biopharmaceutical Sciences from Leiden University. He has the Dutch nationality.